Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Company Overview - Sensei Biotherapeutics, Inc. is a clinical stage biotechnology company focused on developing next-generation therapeutics for cancer patients [3] - The company utilizes its TMAb™ platform to create conditionally active therapeutics that target the tumor microenvironment [3] Product Development - Sensei's lead product candidate is solnerstotug, an antibody designed to block the VISTA checkpoint selectively in the low pH tumor microenvironment [3] - The mechanism of solnerstotug involves disabling immunosuppressive signals to activate T cells against tumors [3] Upcoming Events - John Celebi, President and CEO of Sensei, will present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference on February 11, 2025, at 10:40 a.m. ET [1] - A webcast of the presentation will be available on the company's website, with a replay accessible for approximately 90 days [2]